Search results for "Bio"

Hanmi’s 'Amoprel' Makes Global Waves: World’s First Ultra-Low Triple Hypertension Drug Lands in JACC

Hanmi’s 'Amoprel' Makes Global Waves: World’s First Ultra-Low Triple Hypertension Drug Lands in JACC

The Phase 3 clinical trial results for Hanmi Pharmaceutical’s Amoprel—the world’s first ultra-low-dose triple antihypertensive drug—were published on...
VigenCell

VigenCell "Primary Endpoint Achieved"... Will a Domestic NK/T Lymphoma New Drug Be Born?

VigenCell has announced plans to apply for conditional approval within the year as it successfully completed commercialization clinical trials for...

"Is Waking Up at 5 AM the Key to Success?": The Uncomfortable Truth About Early Rising

At 5 AM, while darkness still lingers, a subset of the population is already turning off alarms to exercise, journal,...
The Electric Bond: How Mussel-Inspired Adhesives are Restoring Severed Nerves

The Electric Bond: How Mussel-Inspired Adhesives are Restoring Severed Nerves

Whether it is a victim of a car accident with severed peripheral nerves, an athlete with a torn muscle, or a patient...
The

The "Mini Jet Lag" of Spring: Why Your Body Struggles with Seasonal Transitions

If your body feels unusually heavy and unrefreshed despite getting enough sleep lately, the culprit may not be your...
Onconic’s ‘Nesuparib’ Secures U.S. FDA Orphan Drug Designation for Small Cell Lung Cancer

Onconic’s ‘Nesuparib’ Secures U.S. FDA Orphan Drug Designation for Small Cell Lung Cancer

Onconic Therapeutics announced on the 24th that its novel anti-cancer candidate, 'Nesuparib', has been designated as an...
U.S. and EU Escalate Pressure on China: A Turning Point for K-Bio?

U.S. and EU Escalate Pressure on China: A Turning Point for K-Bio?

As the United States prepares to announce the initial regulatory targets of the Biosecurity Act this week, market...
K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval

K-Bio Targets Global Expansion: HK inno.N and HLB Seek FDA Approval

South Korean pharmaceutical and biotech companies are aggressively pursuing product approvals and clinical trials with...
Samsung Bioepis Set to Launch Eylea Biosimilar in the U.S. Next January

Samsung Bioepis Set to Launch Eylea Biosimilar in the U.S. Next January

Samsung Bioepis announced on the 12th that it has entered into a patent license agreement with the original developer...
DNA in Blood Speaks of Cancer Traces

DNA in Blood Speaks of Cancer Traces

"Can we detect multiple cancers early with just one blood draw?" As interest grows in diagnostic tests that quickly...